Clinical Research Directory

Inclusion Criteria: * Aged \>18 * Symptomatic AF (paroxysmal or persistent \<12-months) with a rhythm control management strategy selected including consideration of referral for a cardioversion or ablation forming part of their planned pathway * BMI ≥27m/kg2 Exclusion Criteria: * Prognostic coronary artery disease, defined as left main stem \>50% stenosis and/or ≥ moderate disease in ≥3 major epicardial vessels requiring revascularisation. * Unstable angina * New York Heart Association class III/IV heart failure or severe left ventricular impairment * Significant cardiomyopathy (as assessed by Cardiologist, e.g. hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy) * Severe heart valve disease * Severe hypertension (BP \>180/120mmHg) despite optimising anti-hypertensive therapy * Uncontrolled arrhythmia or higher degree heart block * History of aortic dissection * Recent acute pulmonary embolus, deep vein thrombosis, stroke or transient ischaemic attack (\<6 months) * Severe autonomic or peripheral neuropathy * Significant acute or chronic renal failure that would preclude contrast use at CT * Significant pulmonary fibrosis or interstitial lung disease (as assessed by a pulmonary physician) * Physically unable to participate in high-intensity exercise * Pregnancy * Prior AF ablation * A clinically significant ECG abnormality at the screening visit, which in the opinion of the investigators exposes the subject to risk by enrolling in the trial, including but not limited to: sustained ventricular tachycardia, high-grade atrioventricular block (second-degree Mobitz type II or third-degree heart block), evidence of acute ischemia (ST-segment elevation or depression \>1 mm), or other arrhythmias deemed clinically significant by the study cardiologist. * Participation in another intervention-based research study * Inability to fully understand the instructions provided during the study